Recent preclinical trials have revealed a significant breakthrough resistance to anti-PD-1/PD-L1 immunotherapy in various solid tumors, including hepatocellular carcinoma (HCC) and multiple myeloma (MM), is instigated by the up-regulation of CD38 on tumor cells6. The gene discussed is CD38; the disease is Miyoshi myopathy.